Cancer-associated ischemic stroke: pathophysiology, clinical characteristics, and treatment / 国际脑血管病杂志

ABSTRACT

Cancer can mediate the onset of ischemic stroke directly or through cancer-associated hypercoagulability. The clinical manifestations of cancer-associated ischemic stroke (CAIS) are very heterogeneous according to the underlying cause. Generally speaking, CAIS is manifested as multiple vascular territory ischemic lesions on imaging, and fibrinogen degradation products such as blood D-dimer are significantly increased. The treatment of CAIS is quite tricky. Given that the risk of bleeding is not higher than that of the general population, cancer is not a contraindication for intravenous thrombolysis and mechanical thrombectomy. Anticoagulant therapy of CAIS should be individualized according to the benefits and risks. Low molecular weight heparin is still the first choice, and new oral anticoagulants have good prospects. This article reviews the pathogenesis, clinical features and treatment progress of CAIS.